de Leval L, Colombi S, Debrus S, Demoitié M A, Greimers R, Linsley P, Moutschen M, Boniver J
Laboratory of Pathology, University of Liège, Liège, Belgium.
J Virol. 1998 Jun;72(6):5285-90. doi: 10.1128/JVI.72.6.5285-5290.1998.
Mouse AIDS (MAIDS) induced in C57BL/6 mice by infection with a replication-defective retrovirus (Du5H) combines extensive lymphoproliferation and profound immunodeficiency. Although B cells are the main target of viral infection, recent research has focused on CD4(+) T cells, the activation of which is a key event in MAIDS induction and progression. A preliminary observation of increased expression of B7 molecules on B cells in MAIDS prompted us to address the possible involvement of the CD28/B7 costimulatory pathway in MAIDS. Mice infected with the MAIDS-inducing viral preparation were treated with murine fusion protein CTLA4Ig (3 x 50 microg/week given intraperitoneally), a competitive inhibitor of physiological CD28-B7 interactions. In CTLA4Ig-treated animals, the onset of the disease was delayed, lymphoproliferation progressed at a much slower rate than in untreated mice, and the loss of in vitro responsiveness to mitogens was reduced. Relative expression of Du5H did not differ between treated and untreated animals. These results suggest that the CD28/B7 costimulatory pathway contributes to MAIDS development.
通过感染复制缺陷型逆转录病毒(Du5H)在C57BL/6小鼠中诱发的小鼠获得性免疫缺陷综合征(MAIDS)兼具广泛的淋巴细胞增殖和严重的免疫缺陷。虽然B细胞是病毒感染的主要靶标,但最近的研究聚焦于CD4(+) T细胞,其激活是MAIDS诱导和进展过程中的关键事件。对MAIDS中B细胞上B7分子表达增加的初步观察促使我们研究CD28/B7共刺激途径在MAIDS中可能发挥的作用。用小鼠融合蛋白CTLA4Ig(腹腔注射,每周3次,每次50微克)对感染了诱导MAIDS病毒制剂的小鼠进行治疗,CTLA4Ig是生理性CD28 - B7相互作用的竞争性抑制剂。在接受CTLA4Ig治疗的动物中,疾病的发作延迟,淋巴细胞增殖的进展速度比未治疗的小鼠慢得多,并且对有丝分裂原的体外反应性丧失减少。治疗组和未治疗组动物之间Du5H的相对表达没有差异。这些结果表明CD28/B7共刺激途径有助于MAIDS的发展。